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SUMMARY
Small cell lung cancer (SCLC) is an aggressive disease with high mortality. The identification of 
effective pharmacological strategies to target SCLC biology represents an urgent need. Using a 
high-throughput cellular screen of a diverse chemical library we observe that SCLC is sensitive to 
transcription-targeting drugs, and in particular to THZ1, a recent identified covalent inhibitor of 
cyclin-dependent kinase 7 (CDK7). We find that expression of super-enhancer associated 
transcription factor genes including MYC family proto-oncogenes and neuroendocrine lineage-
specific factors are highly vulnerability to THZ1 treatment. We propose that downregulation of 
these transcription factors contributes, in part, to SCLC sensitivity to transcriptional inhibitors and 
that THZ1 represents a prototype drug for tailored SCLC therapy.
INTRODUCTION
Lung cancer accounts for nearly 30% of all cancer-related deaths. In 10–15% of lung cancer 
cases patients are diagnosed with small cell lung cancer (SCLC), the most malignant sub-
type of lung cancer, characterized by aggressive growth, early onset of metastasis, and rapid 
development of chemo-refractory disease. The 5-year survival rate for SCLC patients is less 
than 5%—a poor prognosis that has not changed in four decades due to the lack of 
advancement in SCLC therapeutics (Sato et al., 2007; William and Glisson, 2011). In 
contrast to non-small cell lung cancer (NSCLC) where therapeutics designed to target 
known oncogenic drivers such as EGFR and ALK have been extremely effective; the poor 
understanding of SCLC disease etiology has precluded the identification of therapeutic 
targets and effective treatments (William and Glisson, 2011). Recent efforts to collect and 
sequence SCLC tissues have revealed that these tumors display a strikingly high rate of 
protein-changing mutations (Peifer et al., 2012; Rudin et al., 2012); however, paradoxically, 
no targetable mutations have been identified to guide therapeutic decisions for SCLC, and 
efficient treatment paradigms are urgently needed.
SCLC is defined by the near ubiquitous inactivation of both P53 and RB (Peifer et al., 2012; 
Rudin et al., 2012; Sato et al., 2007); however, recent reports indicate that the cell of origin 
is equally important for the development of SCLC disease. Conditional inactivation of P53 
and RB in the adult mouse lung, using a genetically-engineered mouse (GEM) model, is 
sufficient to develop murine SCLC resembling human disease (Meuwissen et al., 2003). 
Importantly though, SCLC is only firmly established if P53 and RB is inactivated in the 
small population of pulmonary neuroendocrine cells (PNEC) (Sutherland et al., 2011). In 
contrast, P53 and RB loss confined to the abundant non-neuroendocrine cell population in 
the murine lungs cause low penetrance of SCLC and a significant increase in disease latency 
(Park et al., 2011; Sutherland et al., 2011). Thus, the PNEC is the major cell of origin of 
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SCLC, suggesting that neuroendocrine pathways collaborate with P53 and RB loss to initiate 
and drive SCLC tumorigenesis.
SCLC cells (as well as PNECs) exhibit high, sustained expression of many neuroendocrine 
genes, in particular transcription factors that regulate neuroendocrine development and 
differentiation in various tissues (Pedersen et al., 2003; Reynolds et al., 2000; Travis, 2009). 
Achaete-scute homolog 1 (ASCL1) which is a master regulator of neuroendocrine 
differentiation in lung development (Borges et al., 1997; Ito et al., 2000) and has been 
shown to regulate tumor-initiating capacity and survival pathways in SCLC (Jiang et al., 
2009; Osada et al., 2005), hence underscoring the interplay between neuroendocrine 
signaling and SCLC pathogenesis. Furthermore, the lineage-specific transcription factor 
NEUROD1, has been reported to govern survival pathways in SCLC cells (Osborne et al., 
2013). Further, SCLC cells exhibit various chromosomal and focal amplifications leading to 
increased target gene expression and possible gain-of-function. Fifty to eighty percent of 
SCLC tumors exhibit mutually exclusive amplification of the proto-oncogenes MYC, 
MYCN, or MYCL (Brennan et al., 1991; Huijbers et al., 2014; Johnson et al., 1987; Kim et 
al., 2006; Peifer et al., 2012; Rudin et al., 2012; Voortman et al., 2010). MYC is 
misregulated in the majority of human cancers leading to uncontrolled proliferation possible 
through augmentation of existing gene expression programs (Lin et al., 2012). In contrast to 
MYC, MYCN and MYCL misregulation occurs only in high-risk cancers of neuroendocrine 
origin such as SCLC (Huijbers et al., 2014; Johnson et al., 1987; McFadden et al., 2014), 
neuroblastoma (MYCN) (Huang and Weiss, 2013), and medulloblastoma (MYCN, MYCL) 
(Northcott et al., 2012). Moreover, many SCLC tumors have focal amplifications or 
increased expression of SOX-family genes (Voortman et al., 2010), including SOX2, which 
is critical for lung development and self-renewal. SOX2 amplification and increased 
expression levels in tumors correlates with accelerated disease stage and silencing of SOX2 
inhibits growth of SCLC cells (Rudin et al., 2012).
Thus, misregulated and amplified lineage-specific and proto-oncogenic transcription factors 
appear to govern SCLC initiation and disease evolution and downregulation of such factors 
could form the basis for SCLC targeted therapy.
Using an unbiased small molecule screen approach we indeed observed that SCLC is highly 
sensitive to transcription-targeting drugs and in particularly to a covalent inhibitor of cyclin-
dependent kinase 7 (CDK7), THZ1, which can drastically reduce RNAPII-mediated gene 
transcription (Kwiatkowski et al., 2014). Here, we sought to investigate the therapeutic 
potential of THZ1 in SCLC pre-clinical models and further use THZ1 as a chemical tool to 
dissect the malignant transcriptional programs driving SCLC state.
RESULTS
High-throughput small-molecule drug screen identifies THZ1 as a highly potent inhibitor of 
SCLC viability
To identify small molecules that suppress SCLC cell growth we performed an unbiased 
high-throughput screen in SCLC cells lines using a library of greater than 1000 annotated 
small molecule inhibitors composed of both experimental compounds and early or advanced 
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clinical candidates. To minimize artefacts that may arise from long-term culture of SCLC 
cell lines we employed low-passage (passage 5–10), primary murine SCLC (mSCLC) cell 
lines, established from mSCLC tumors isolated from the GEM model of SCLC consisting of 
the RbL/L;p53L/L (RP) allelic genotype (Meuwissen et al., 2003) (Figure 1A). To account for 
tumor heterogeneity, a total of 3 mSCLC cell lines (termed mSCLC1, 2, and 3), each from a 
different tumor-bearing RP mouse, were used to establish cell lines for the screen (Figure 
1A). Importantly, all established mSCLC cell lines displayed morphology that is 
characteristic of SCLC by growing as suspension cells in floating aggregates and spheres 
(Figure 1A). Furthermore, the established mSCLC cells expressed classical SCLC-specific 
(neuroendocrine) markers (Figure S1A). Using a cell viability assay compounds were 
initially screened at a single dose on the mSCLC cells. Forty-five compounds elicited 
greater than 50% reduction in growth and were triaged for further inspection (Figure 1B). 
Fifteen compounds resulted in a mean anti-proliferation IC50 across 3 SCLC cell lines of 
less than 300 nM (Figure 1C). The top ranked inhibitors fell broadly into three major 
putative categories of inhibitors of 1) transcription (THZ1, Flavopiridol, CGP60474, JQ1, 
NVP-AUY922, 17-DMAG, BI2536), 2) cell cycle function (BI2536, CGP60474, AZD7762, 
ON-01910, PF477736, XMD16-144, THZ1), 3) mTOR-PI3K pathway (GSK2126458, 
PIK75, Torin 2) (Figure 1C–D).
SCLC cell lines demonstrate particular sensitivity to transcriptional inhibition with the top 3 
scoring small molecule inhibitors from the screen (NVP-AUY922, BI2536, THZ1) targeting 
proteins involved in transcriptional regulation. NVP-AUY922 targets HSP90, which has 
recently been shown to be involved in regulating RNAPII pausing and transcriptional 
activation (Sawarkar et al., 2012). BI-2536, known as a polo-like 1 (PLK1) kinase inhibitor, 
has recently been shown to cross-react with bromodomain 4 (BRD4), a general co-activator 
of gene expression (Ember et al., 2014). The bromodomain (BRD) inhibitor JQ1 
(Filippakopoulos et al., 2010) also ranked within the top-15 inhibitors (Figure 1C). 
Disappointingly however, despite displaying efficacy in tumor cell lines, clinical trials with 
both HSP90 inhibitors and PLK1 inhibitors have in general fared poorly. As a result, we 
focused much of our attention on THZ1, a recently identified covalent CDK7 inhibitor with 
additional cross reactivity against CDK12/13. THZ1 has recently been demonstrated to 
decrease T-cell acute lymphoblastic leukemia (T-ALL) viability, in part, through 
downregulation of key oncogenic transcription factors (Kwiatkowski et al., 2014). We 
speculated that the high ranking of THZ1 in the drug screen could indicate that SCLC 
exhibits similar dependencies for the expression of oncogenic transcription factors.
We compared the observed effects of THZ1 in murine SCLC cells with that of mutant Kras-
driven murine NSCLC (mNSCLC) cell lines (Liu et al., 2013). THZ1 displayed an IC50 
value of 75–100 nM against mSCLC cells, while mNSCLC cells were greater than 5-fold 
less sensitive to THZ1 treatment with IC50 around 1000 nM or greater (Figure 1E). These 
data suggest that lung cancer types addicted to mutated kinases are relatively less vulnerable 
to transcription-targeting drugs than SCLC. When testing several commercially available 
pan-CDK inhibitors targeting one or more of the higher-order transcriptional CDKs such as 
CDK7, 8, and 9, we found that apart from Flavopiridol and Dinaciclib, all compounds had 
an IC50 exceeding 500 or 1000 nM (Figure S1B–D). Dinaciclib and Flavopiridol showed 
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potency at a nanomolar scale similar to THZ1, but did not exhibit SCLC-specificity since 
Kras-driven NSCLC cell lines were equally sensitive to compounds (Figure S1B–C). As 
previously observed (Kwiatkowski et al., 2014), THZ1 facilitated irreversible (covalent) 
binding to CDK7 (Figure S1E) and a non-covalent version of THZ1 (THZ1-R) was 
significantly less potent (Figure S1F). Hence, THZ1 potently and selectively inhibits SCLC 
cell viability and its induced cellular effects results in part, in part, from its irreversible 
covalent inhibition of CDK7. Both Flavopiridol and THZ1 have been shown to cross react 
with CDK12/13 at higher concentrations (Bosken et al., 2014; Kwiatkowski et al., 2014), 
therefore this shared pharmacology may also impact the transcriptional and phenotypic 
response of SCLC to these inhibitors.
Mice with aggressive autochthonous SCLC disease show significant tumor response 
following THZ1 treatment
To establish the translational significance of the observed potency of THZ1 in SCLC cells, 
we tested THZ1 in vivo in the RP GEM model. This autochthonous mouse model offers a 
pre-clinical platform with remarkable resemblance to the human SCLC disease (Meuwissen 
et al., 2003). The concomitant loss of p53 and Rb function in the adult murine lung tissue 
allows for a stochastic and heterogeneous disease course with aggressively growing primary 
lung tumor and metastasis. Disease course in RP mice was followed by magnetic resonance 
imaging (MRI) of the thorax region, and upon detectable lung tumor burden, mice were 
started on treatment with either THZ1 or vehicle. We additionally treated a cohort of mice 
with Cisplatin and Etoposide (Cis-Eto) to allow for comparison to the standard-of-care 
chemotherapy regimen used in the clinic for SCLC patients. MRI was performed every two 
weeks after treatment start in the three different treatment cohorts (Figure 2A–F). All 
vehicle-treated mice showed progressive disease (PD – more than 20% increase in tumor 
volume compared to baseline) with up to more than doubling of tumor volume at the 2-week 
time point (Figure 2B, F). THZ1-treated mice had significant tumor response compared to 
control at the two-week time point (Figure 2B, C, F; Figure S2A). Three of nine THZ1-
treated mice showed partial response (PR – more than 30% tumor volume reduction 
compared to baseline), and two of those had near-complete response with more than 90% 
reduction in tumor burden. Four THZ1-treated mice had stable disease (SD - neither 
reduction nor increase in tumor volume to classify as PR or PD), while two THZ1-treated 
mice had PD. Further, the majority of THZ1-treated mice with SD or PR at the two-week 
time point had similar disease responses at the four-week time point (Figure 2B–C, F, Figure 
S2A). In contrast, most vehicle-treated mice succumbed to their tumor burden before the 
four-week time point (4 out of 6 mice), emphasizing the aggressive disease course in the 
SCLC GEM model (Figure 2B, E). Overall, THZ1-treated mice had longer survival 
compared to control-treated mice (p=0.0011) (Figure 2E). Furthermore, we observed that 
response rates and survival obtained from single agent THZ1 treatment were comparable to 
tumor response rates upon standard-of-care chemotherapy (Figure 2B–F). However, THZ1 
treatment did not result in treatment-related toxicity in RP mice in contrast to Cis-Eto 
treatment (Figure 2D). The lack of observed toxicity in THZ1-treated mice suggests that 
THZ1 treatment allows for a broader therapeutic window in cancer versus normal cells 
compared to chemotherapy.
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To investigate whether single agent activity of THZ1 or Cis-Eto could be augmented by a 
combined treatment regimen, we treated an additional cohort of RP mice with THZ1 
combined with Cis-Eto. Our results indicate that, THZ1-Cis-Eto treated mice do not 
experience superior tumor response at 4-week time point compared to mice receiving THZ1 
or Cis-Eto alone (Figure S2B–E). Of note, we did not observe increased toxicity in THZ1-
Cis-Eto treated mice compared to Cis-Eto treatment alone (Figure S2C).
THZ1 treatment resulted in decreased RNAPII CTD phosphorylation in SCLC tumor tissue 
as compared to vehicle-treated mice (Figure S2F) consistent with THZ1 binding and 
inhibition of CDK7 in tumor tissue. Tissue from both lung tumors (n=3) and liver 
metastases (n=1) isolated from THZ1-treated mice had significant more apoptotic cells than 
vehicle-treated tumor tissue as measured by TUNEL staining (Figure 2G, S2G). 
Additionally, mSCLC cells established from SCLC lung tumors and from liver metastases 
showed equal sensitivity to THZ1 indicating that both primary and metastatic SCLC lesions 
are responsive to THZ1 treatment (Figure 2H). Importantly, we found that mSCLC cells 
established from tumors from chemo-treated (resistant) SCLC RP mice had similar 
sensitivity to THZ1 when compared to mSCLC cell lines established from untreated 
(chemo-naïve) RP mice (Figure 2I). Thus, these data suggest that both chemo-naïve and –
refractory SCLC disease is sensitive to THZ1 treatment.
Cellular and tumor models of human SCLC with distinct genotypes and phenotypes are 
highly sensitive to THZ1
To further confirm THZ1 as a drug candidate for patient disease we investigated THZ1 
potency in a panel of genotypically-distinct human (hSCLC) cell lines. hSCLC cell lines are 
known to harbor a complex genome with high mutation rate, frequent copy number gains 
and losses, and translocations (Peifer et al., 2012; Pleasance et al., 2010; Rudin et al., 2012). 
The major identified alterations in the hSCLC cell lines, apart from the mutations in P53 and 
RB, include amplification of MYC, MYCL, or MYCN (Johnson et al., 1987). We used a panel 
of hSCLC cell lines harboring amplifications in each of the MYC genes. Additionally, we 
investigated SCLC tumor cells from chemo-naïve and chemo-treated patients as well as 
those isolated from primary lung sites and from metastatic lesions (Figure 3A). All hSCLC 
cell lines exhibited high sensitivity to THZ1, with an IC50 in the range of 5–20 nM [Figure 
3A (all), Figure 3B upper panel (representative)]. The NCI-H69, GLC16 and NCI-H82 cell 
lines established from chemo-treated patients were less sensitive to Cisplatin-Etoposide 
treatment than the chemo-naïve cell line NCI-H209 (Figure 3B lower panel). THZ1 
treatment of tumor xenografts established from NCI-H69 and GLC16 cells resulted in 
significant tumor growth reduction compared to control-treated tumors, indicating that 
chemo-refractory disease is sensitive to THZ1 treatment (Figure 3C). As in GEM mice, no 
overt toxicity was observed from THZ1 treatment (Figure 3C, inserts). In contrast to hSCLC 
cells, immortalized tracheobronchial epithelial (hTBE) cells showed very little sensitivity to 
THZ1 but similar sensitivity to Cisplatin-Etoposide (Figure 3B), reinforcing previous 
observations that THZ1 treatment confers a superior therapeutic window between cancer 
and non-cancer cells compared to chemotherapy.
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Significant induction of apoptosis was observed in hSCLC cells as early as 6 hours after 
exposure to THZ1 (Figure 3D) and significant inhibition of proliferation occurred at 24 and 
48 hours after exposure (Figure 3E). The appearance of apoptotic markers appeared 
concomitant with decrease of RNAPII CTD phosphorylation (Figure 3D, F). In line with 
these results we observed that the classical sphere-forming morphology of SCLC cells was 
dramatically disrupted after only 12 hours exposure to THZ1 in 3D culture (Figure S3A). 
Similar differential sensitivity was observed between hSCLC and hNSCLC cells (Figure 
S3B–E), as previously noted in the murine cellular lung cancer models (Figure 1E). As 
observed in the mSCLC cell lines, most pan-CDK inhibitors tested showed either less 
potency in hSCLC cells or less SCLC-specificity (Figure S3C–E). Furthermore, we 
observed significantly lower potency of THZ1-R compared to THZ1, again confirming that 
the covalent mechanism of action of THZ1 is critical for drug potency (Figure S3F–G).
THZ1 confers preferential repression of transcription-regulating genes in SCLC cells
Intrigued by the significant therapeutic response in various preclinical models of SCLC 
disease, we aimed to understand the mechanisms governing SCLC sensitivity to THZ1. 
CDK7 is a component of the general transcription factor IIH (TFIIH), which activates 
RNAPII-mediated transcription. Consistent with this notion, high dose treatment with THZ1 
in Jurkat cells was previously shown to cause pronounced global downregulation of gene 
expression; however, low dose THZ1 produced gene selective effects on the Jurkat 
interconnected transcriptional core regulatory circuitry (Kwiatkowski et al., 2014). To 
investigate THZ1-induced transcriptional effects in SCLC, we performed gene expression 
profiling in selected hSCLC cell lines; NCI-H69, GLC16 and NCI-H82; following treatment 
with 25 nM and 100 nM THZ1, which are concentrations at which limited and substantial 
inhibition of RNAPII phosphorylation are achieved, respectively (Figure 3F). Across SCLC 
cell lines, treatment with THZ1 led to a reduction in steady-state mRNA levels with 0.2–5% 
and 13–27% of mRNAs showing greater than 2-fold reduction at 25 and 100 nM, 
respectively (Figure 4A–B, Table S1, Table S2). Gene ontology (GO) analysis revealed a 
very significant enrichment of genes involved in transcription among the top-5% of 
downregulated genes after 100 nM THZ1 treatment (Figure 4C). In particular the major part 
of THZ1-sensitive transcripts is associated with DNA-dependent transcription indicating 
transcription factor function (Figure 4C). Moreover, gene set enrichment analysis of 
transcription factor binding sites showed that genes containing binding motifs for master 
regulatory transcription factors such as E2F, NRF1, and CREB were preferentially affected 
by THZ1 treatment (Figure S4A). In particular, we observed that short-lived transcripts of 
the E2F family were heavily downregulated and that E2F-regulated gene sets were 
significantly enriched in THZ1-downregulated transcripts (Figure S4B–C). Interestingly, 
E2F transcription factor binding sites are significantly enriched in the SCLC cells compared 
to the NSCLC (Figure S4D–E) suggesting that E2F transcription factors have a more 
prominent role in SCLC biology.
Proto-oncogenic and lineage-specific transcription factors are associated 
with super-enhancers in SCLC—Little is known about the transcription factors and co-
factors that govern the pathogenesis of SCLC. Genes encoding important regulators of cell 
state, including key oncogenic transcription factors were recently shown to be preferentially 
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associated with unusually large transcriptional regulatory domains known as super-
enhancers (Hnisz et al., 2013; Loven et al., 2013). Furthermore, previous work has 
demonstrated that expression of super-enhancer associated genes can be especially 
vulnerable to transcriptional inhibitors (Chapuy et al., 2013; Hnisz et al., 2013; Kwiatkowski 
et al., 2014; Loven et al., 2013; Whyte et al., 2013). Therefore the identification of super-
enhancers in SCLC may enumerate candidate SCLC oncogenes and focus our search for 
THZ1-responsive transcripts whose downregulation lead to loss of SCLC cell state.
To identify super-enhancers in SCLC cells, we performed ChIP-seq against the lysine 27 
acetylated form of histone H3 (H3K27Ac) in untreated hSCLC cells. H3K27Ac defines 
active enhancers and has been used previously to determine the position and size of super-
enhancers (Hnisz et al., 2013). Using this approach, we identified 130 super-enhancer-
associated genes in NCI-H69, 103 in GLC16, and 70 in NCI-H82 (Table S3, Figure 5A–D).
We found that many super-enhancer associated genes encode gene products involved in 
regulation of RNAPII-mediated transcription (Figure 5A, B). This indicates that many 
transcription factors are important to SCLC state and might represent candidate oncogenes. 
The super-enhancer landscape recapitulated the embryonic and neural signature common to 
SCLC cells. Many super-enhancers were found to be associated with genes encoding 
lineage-specific transcription factors that are central regulators of embryogenesis and neural 
development (Figure 5A–B). Consistent with previous investigations observing differential 
gene expression profiles between the so-called ‘classical’ and ‘variant’ SCLC cell lines 
(Johnson et al., 1987; Pedersen et al., 2003) we found that the ‘classical’ GLC16 and NCI-
H69 cell lines had significant overlap in identified super-enhancer genes while the ‘variant’ 
NCI-H82 cell line had a distinct super-enhancer profile from the classical cell lines (Figure 
5B–C).
In both NCI-H69 and GLC16 cell lines, we identified super-enhancers associated with SOX2 
and NFIB (Figure 5A, D) consistent with their proposed role as proto-oncogenic 
transcription factors in SCLC (Dooley et al., 2011; Rudin et al., 2012). Similarly, the 
neuroendocrine master transcription factor gene ASCL1 (Borges et al., 1997; Ito et al., 2000) 
was associated with one of the largest typical enhancers (Figure 5A, D, Table S2). 
Moreover, we identified many super-enhancer associated transcription factor genes in 
GLC16 and NCI-H69 whose functions were not previously described in the context of 
SCLC biology. Among them was Insulinoma-associated 1 (INSM1) (Figure 5A, D, Table 
S3), which represent a highly predictive marker of SCLC disease (Figure S5) (Christensen et 
al., 2010; Lan and Breslin, 2009; Pedersen et al., 2003). In the NCI-H82 cell line, we 
identified a super-enhancer at the OTX2 gene, which encodes a transcription factor involved 
in neural differentiation and development. Similar to INSM1, the functional role of OTX2 in 
SCLC biology is unknown. Moreover, we identified large typical enhancers associated with 
the proto-oncogenic neuroendocrine transcription factor genes NEUROD1 (Figure 5A, D, 
S5, Table S3) (Osborne et al., 2013).
Super-enhancers were found to be associated with genes that had focal amplification. The C-
MYC amplified cell lines GLC16 and NCI-H82 and the MYCN amplified cell line NCI-H69 
(Figure 3A) had super-enhancers associated with C-MYC and MYCN gene loci respectively 
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(Figure 5A, 5D). In the NCI-H69 cell lines the MYCN super-enhancer ranked second largest 
and in NCI-H82 the two largest super-enhancers were both found in the C-MYC gene loci 
(Table S3). Interestingly, we in addition found evidence for focal amplification of OTX2 in 
the NCI-H82 cell line (Figure 5D).
Super-enhancer associated genes are disproportionally vulnerable to THZ1 treatment
Next we aimed to investigate whether THZ1 conferred preferential repression of super-
enhancer associated genes in SCLC (Figure 6A–C). Enrichment analysis of THZ1-sensitive 
transcripts (Figure 4, Table S2) and super-enhancer associated genes (Table S3) showed that 
THZ1-targeted transcripts are enriched in the gene sets with associated super-enhancers 
(FDR<0.05) (Figure 6A, Table S4). Moreover, mean transcript abundance associated with 
super-enhancers (SEs) was disproportionately reduced upon THZ1 exposure compared to 
that of typical enhancers (TEs) (Figure 6B). This disproportionate reduction was observed 
even at the low dose (25 nM) of THZ1, which produces limited repression of RNAPII-
mediated transcription (Figure 3F). In addition genes associated with the top ranked (largest) 
TE (TOPTE) were more sensitive to THZ1 treatment than genes associated with a general 
TE (Figure 6B) emphasizing that enhancer size is positively correlated with THZ1 
vulnerability.
In order to focus our search for SCLC oncogenic transcription factors we identified a 
leading-edge gene set consisting of super-enhancer associated transcripts that were 
significantly downregulated by THZ1 (Figure 6C). As oncogenic transcription factors are 
often highly expressed we further filtered our leading-edge gene set (Figure 6C) to contain 
the top 5 % actively expressed genes (Figure 6D). Confirmative of this scheme, MYC-family 
of proto-oncogenes placed among the leading-edge gene set and was among the top 5 % 
most actively expressed genes in the analyzed hSCLC cells (Figure 6D). Using this 
approach we further identified SOX2, SOX4, NFIB, INSM1 (NCI-H69, GLC16) and OTX2 
(NCI-H82). ASCL1 (NCI-H69, GLC16) and NEUROD1 (NCI-H82) both associated with a 
TOPTE, but were both highly reduced in THZ1-treated cells and ranked among the top 5 % 
actively expressed genes (Figure 6C–D). The downregulation of the transcription factor 
genes were confirmed on RNA level by quantitative PCR (Figure 6E) and selected 
transcripts further confirmed on protein level (Figure 6F). The reduced transcript level of 
SCLC-specific transcription factors observed in vitro was furthermore confirmed in vivo in 
THZ1-treated RP mice (Figure S6).
DISCUSSION
Here, we addressed a high therapeutic need by identifying THZ1 (Kwiatkowski et al., 2014), 
as a promising drug candidate for the treatment of SCLC. While recent sequencing efforts 
revealed that SCLC tumors contain a high rate of protein-altering mutations, the mapping of 
the mutational landscape did not guide in therapeutic decisions for this fatal disease (Peifer 
et al., 2012; Rudin et al., 2012). Using an unbiased small molecule screen approach we 
observed that SCLC cells were highly vulnerable to perturbation of the transcriptional state 
since several transcriptional inhibitors were potent inhibitors of SCLC cell viability. The 
high potency of THZ1 in SCLC cells was further confirmed in vivo in the RP GEM mice 
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model, which represents a highly translational preclinical platform for the investigation of 
SCLC therapeutics (Meuwissen et al., 2003). The RP GEM model mimics the stochastic and 
heterogeneous pathogenesis in human disease and mSCLC tumors have been shown to 
accumulate additional alterations as observed in human disease, such as amplification of 
MYCL (McFadden et al., 2014; Peifer et al., 2012). We observed significant tumor responses 
in SCLC GEM mice treated with THZ1 compared to control-treated mice and further noted 
that standard-of-care chemotherapy caused similar response rates in SCLC GEM mice. 
However, while chemotherapy was associated with toxicity, THZ1 treatment did not cause 
any overt toxicity in treated mice. Furthermore our treatment data in both murine and human 
pre-clinical models of SCLC indicate that both metastatic and chemo-refractory SCLC 
disease is sensitive to THZ1 treatment.
The encouraging preclinical results led us to investigate the transcriptional addictions of 
SCLC. Due to the preponderance of misregulated transcription factors in SCLC (Dooley et 
al., 2011; Jiang et al., 2009; Johnson et al., 1987; Osborne et al., 2013; Pedersen et al., 2003; 
Rudin et al., 2012; Voortman et al., 2010), we aimed to identify a candidate list of 
transcription factor genes associated with super-enhancers (Chapuy et al., 2013; Hnisz et al., 
2013; Kwiatkowski et al., 2014; Loven et al., 2013; Whyte et al., 2013) and whose high-
level expression were particular vulnerable to THZ1 treatment. We hypothesized that such a 
list would represent candidate oncogenic transcription factors in SCLC disease.
Affirmative of this scheme, we identified that the focally amplified C-MYC (in GLC16 and 
NCI-H82 cells) and MYCN (in NCI-H69 cells) proto-oncogenes (Brennan et al., 1991; 
Voortman et al., 2010)were associated with large super-enhancers and were highly 
vulnerable to THZ1. We did not observe differential sensitivity to THZ1 between SCLC 
cells with genomic amplification of either MYCN, C-MYC, or MYCL and cell lines without 
amplification, therefore suggesting that MYC amplification is not a biomarker per se for 
THZ1-sensitive SCLC. Since focal amplification of MYC gene members is associated with 
later-stage disease and, possibly, chemo-resistant disease (Brennan et al., 1991; Johnson et 
al., 1987), these data further support that THZ1 treatment will be effective in progressive 
aggressive SCLC disease stages.
In contrast to MYC amplifications, the transcriptional-amplified neuroendocrine gene 
program is an early and possible contributing event of SCLC disease, in which PNECs are 
believed to be the cell of origin (Park et al., 2011; Sutherland et al., 2011). The PNECs are 
abundant in the developing lung, where they play a role in lung branching morphogenesis 
and oxygen sensing. The purpose and function of the small population (<0.5 %) of PNECs 
maintained in the adult lung epithelium is not known (Reynolds et al., 2000; Travis, 2009). 
While the neuroendocrine signature of SCLC has been a central diagnostic tool only few 
functional studies have been performed to explore if and how the malignant neuroendocrine 
factors contribute to SCLC disease (Ball, 2004; Lan and Breslin, 2009). We identified a top-
ranked (large) typical enhancer (TOPTE) associated with ASCL1, in support of its 
established role as a master transcription factor in lung neuroendocrine differentiation 
(Borges et al., 1997) and as a proposed candidate oncogene in SCLC (Jiang et al., 2009). 
Our results greatly corroborate these findings as we observe that ASCL1 is among the 
top-2% most downregulated genes in THZ1-treated cells. We further identified several 
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candidate oncogenic transcription factors in SCLC. One example is the neuroendocrine 
transcription factor INSM1, which is represent a highly lineage-defining trait of SCLC. 
INSM1 phenocopies ASCL1 function in murine neural development but it is not known 
whether same functional link exist in SCLC biology (Ball, 2004; Lan and Breslin, 2009). 
Future work should investigate the role of INSM1 and other transcription factors in the 
malignant transcriptional gene programs that drive and maintain SCLC disease.
Our chemical screen revealed that 7 out of 15 compounds identified as potent inhibitors of 
SCLC cell viability are transcriptional inhibitors. Hence, further pharmacological studies of 
small molecules targeting the general transcription apparatus, should be performed to 
advance the field of SCLC-tailored therapeutics and to uncover the transcriptional addictions 
of SCLC.
EXPERIMENTAL PROCEDURES
Generation of genetically engineered mouse (GEM) model of SCLC and murine SCLC cell 
lines
Mice were bred to contain conditional p53 floxed (L) allele (Jonkers et al., 2001) and Rb 
floxed (L) allele (Meuwissen et al., 2003) to a final genotype of RbL/L;p53L/L (RP). All 
experimental mice were maintained on a mixed genetic background (C57Bl/6, Balb-c, and 
S129). From 6 weeks of age mice were induced with Adenovirus-Cre recombinase (Ad-Cre) 
by intratracheal intubation (DuPage et al., 2009) to allow for cre-lox mediated 
recombination of floxed p53 and Rb alleles. Mice were aged 8–12 months to allow for 
SCLC disease development. The Animal Care and Use Committee of the Dana-Farber 
Cancer Institute approved all in vivo experiments performed in this study. Murine SCLC cell 
lines (mSCLC) were established from RP tumors upon mechanical dissection of tissue. Cells 
were established and maintained in HITES medium (Carney et al., 1981) with 10 % FBS 
and cultured at 37°C in a humidified chamber with 5 % CO2. Extracted DNA from cell lines 
were evaluated for p53 and Rb recombination as previously described (Jonkers et al., 2001; 
Meuwissen et al., 2003). Cell stocks were frozen at very low passage (p=5) for use in screen 
experiments.
High-throughput small molecule screen
Using a semi-automated platform we tested >1000 small molecule annotated library. in 3 
mSCLC cell lines (termed mSCLC1, 2, and 3). Cells were seeded in a 384-well format and 
treated with a concentration of 600 nM of individual compounds before evaluating cell 
viability after 120 hours (2 doubling times) using CellTiter-Glo Lumeniscent assay 
(Promega). Further evaluation of compounds which allowed for more than 50% inhibition of 
cell viability was performed in a 5-point 2-fold dilution series of each compound before 
evaluating cell viability after 120 hours using CellTiter-Glo (experimental repeat 1) or MTS-
based CKK-8 assay (Dojindo) (experimental repeat 2).
See Supplemental Experimental Procedures.
Genetically engineered mice (GEM) dosing studies and Magnetic Resonance 
Imaging—Mice were imaged on a 7 Tesla BioSpec; Bruker BioSpin) with MRI protocols 
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optimized for image requisition of pulmonary parenchyma and vessels in healthy mice. 
Upon determination of tumor growth mice were randomized into treatment groups receiving 
either THZ (Kwiatkowski et al., 2014), Cisplatin-Etoposide or vehicle.
See Supplemental Experimental Procedures.
RNA extraction and Synthetic RNA Spike-In
In short, total RNA from human SCLC cells was prepared using ERCC RNA Spike-In Mix 
(Ambion) as previously described (Loven et al., 2012).
See supplemental Experimental Procedures
Microarray Sample Preparation and Analysis
Gene expression analysis on spiked-in RNA samples was performed using Human 
PrimeView array (Affymetrix) as previously described (Kwiatkowski et al., 2014).
See supplemental Experimental Procedures
Chromatin Immunoprecipitation, sequencing and analysis
Human SCLC cells were cross-linked and incubated with magnetic bead bound-antibody for 
H3K27Ac (Abcam) before sonication to achieve DNA fragment of 200–250 basepair. 
Crosslinks of precipitated protein-DNA complexes were hereafter reversed and sequencing 
was performed using Illumina HiSeq 2000.
See Supplemental Experimental Procedures.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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SIGNIFICANCE
In contrast to other lung carcinomas, there has been no significant progress in the 
development of SCLC therapies since the introduction of chemotherapy in the 1970s. 
Although SCLC tumors exhibit a complex genome with a high mutation rate, genomic 
characterization of SCLC has thus far not revealed druggable oncogenes. Here we find 
that inhibitors of the general transcription apparatus, including a covalent inhibitor of 
CDK7 (THZ1), potently suppress SCLC growth. We identify a number of THZ1-
responsive transcripts, including super-enhancer-associated proto-oncogenic and lineage-
specific transcription factors, whose vulnerability to THZ1 contributes to SCLC 
sensitivity. Our data suggests that THZ1 can effectively target these candidate SCLC 
proto-oncogenes leading to a viable therapeutic window for effective SCLC therapy.
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HIGHLIGHTS
• SCLC is vulnerable to inhibition of RNAPII-mediated transcription by THZ1
• SCLC super-enhancers associate with proto-oncogenes and key SCLC identity 
genes
• THZ1 preferentially targets super-enhancer-driven transcription factor genes
• THZ1 represents a promising experimental agent for the treatment of SCLC
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Figure 1. High-throughput drug screen in primary murine SCLC cell lines identifies THZ1 as a 
highly potent inhibitor of SCLC cell viability
A) Murine SCLC cell lines (mSCLC1, mSCLC2, mSCLC3) were established from 3 
different adenovirus-Cre recombinase (Ad-Cre)-induced RbL/L;p53L/L (RP) mice aged 8–10 
months. Representative morphology of established primary mSCLC cells is shown to the 
right in the panel. Black scale bar shown in micrographs represent 50μm.
B) >1000 small-molecule inhibitors were included in a high-throughput screen using 
mSCLC1, mSCLC2 and mSCLC3 cell lines at passage 5–10. All drugs were added to each 
cell line (day 0) at a concentration of 600 nM, and cell viability was measured at day 5, 
allowing for 2 doubling cycles of (control) cells. The inhibitors, which reduced cell viability 
by 50 % (compared to no drug control), were further ranked following dose escalation 
treatment to determine IC50 of cell viability. Fifteen compounds had an IC50 below 300 nM 
according to both cell viability assays.
C) Summary of top-15 ranked small molecules and corresponding targets as represented in 
an ‘IC50 heatmap’ format.
D) Distribution of putative targets of top-15 ranked small molecules with targets categorized 
as regulating 1) transcription (indicated with green bar), 2) cell cycle (yellow bar) or 3) 
PI3K-mTOR pathway (brown bar).
E) mSCLC and mNSCLC cell lines (mNSCLC1: Kras+/LSL-G12D;p53L/L, mNSCLC2: 
Kras+/LSL-G12;;p53L/L;Lkb1L/L) were incubated with increasing doses of THZ1 and IC50 
were measured by cell viability assay. Data are presented as mean +/− SEM.
See also Figure S1.
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Figure 2. THZ1 treatment of RP mice causes significant tumor response and increased survival
A) Schematic overview of treatment trial with vehicle (control), THZ1 or Cisplatin-
Etoposide compared to vehicle (control) in RP mice with confirmed (by MRI) SCLC 
disease. THZ1 is dosed at 10 mg/kg BID, Cisplatin-Etoposide (Cis-Eto) is dosed as follow: 
Cisplatin 5 mg/kg 1x per week, Etoposide 10 mg/kg 3x per week. Cis-Eto is given 1–2 
weeks on (pending weight/toxicity) hereafter 2–3 weeks off followed by 1–2 weeks re-
treatment (pending weight/toxicity and tumor burden according to MRI). After treatment 
start MRI was performed biweekly in all treatment cohorts.
B) Tumor volume changes (%) according to MRI quantification in vehicle-treated (control), 
THZ1-treated and Cisplatin-Etoposide-treated mice at 2 and 4 weeks as normalized to pre-
treatment (week 0) tumor volume. p-values between different treatment cohorts were 
calculated using Students t-test. Data are shown as individual values for tumor volume 
change (dots or squares) with horizontal line representing mean.
C) Treatment response as divided into PD (progressive disease), SD (stable disease), and PR 
(partial response) groups in mice treated with vehicle (control), THZ1 or Cis-Eto. Data is 
shown as percent of total mice in respective treatment cohort.
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D) Toxicity events observed in mice treated with THZ1 or Cis-Eto as measured by weight 
loss in mice. If an animal’s weight decreased to 15 % or below (compared to pre-treatment 
weight) during the treatment study, animal was recorded to have treatment-induced toxicity. 
Data is shown as percent (%) of total mice in treatment cohort.
E) Survival of control, THZ1-treated and Cis-Eto-treated mice. p-value was established 
using log-rank test (Mantel-Cox test).
F) Representative MRIs of thorax region of mice treated with vehicle (control), THZ1 or 
Cis-Eto at 2 and 4 weeks.
G) Representative 20x field micrographs (inserts 40x field) of Terminal deoxynucleotidyl 
transferase dUTP nick end-labeling (TUNEL) staining of lung tumor and liver metastases 72 
hours after treatment with THZ1 or vehicle. Black scale bar in micrographs (20x) represent 
50μm. Black scale bar in insert (40x) represent 25μm.
H) Primary (lung) and metastatic (liver) SCLC lesions were isolated from Ad-Cre induced 
RP mice for cell line establishment. Cells established from lung tumor (primary) and 
metastatic (liver tumor) origin were incubated with increasing doses of THZ1, and the IC50s 
were determined by cell viability assay. IC50 from several different cell lines of either group 
are plotted to give a total calculated mean IC50 (horizontal line) with error bars representing 
SEM.
I) SCLC tumor lesions from the lung were isolated from untreated RP mice (n=2) and 
chemo-treated mice (n=2) for establishment of primary cell lines. Primary cells (at passage 
5) were incubated with increasing doses of Cis-Eto (right) or THZ1 (left) and the IC50s 
were determined by cell viability assay. IC50 from several different cell lines of either group 
are plotted (squares or dots) to give a total calculated mean IC50 (horizontal line) with error 
bars representing SEM.
See also Figure S2.
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Figure 3. THZ1 is a potent inhibitor of cell viability and tumor growth in a panel of genotypic 
and phenotypic distinct SCLC cell lines and xenografts
A) Summary of THZ1 IC50s in the full panel of SCLC cell lines with genotype and 
phenotype status. IC50 data are presented as mean with confidence interval (mean [CI]). 
Phenotype profile information on cell lines comprises the following: origin - organ of origin 
of tissue specimen from which cell line was established; chemotherapy - whether patients 
had received chemotherapy before cell line establishment (yes/no). Genetic profile 
information on cell lines includes: P53 and RB mutations (both leading to loss of function) 
and MYC gene family amplification (C-MYC, MYCN or MYCL). * indicates that cell lines 
have previously been classified as ‘variant’ neuroendocrine SCLC cell line based on the lack 
of expression of ‘classical’ neuroendocrine genes such as ASCL1, NCAM, SCG2.
B) Representative hSCLC cell lines (from A)) and the immortalized tracheobronchial 
epithelial (hTBE) cell line were exposed to increasing doses of THZ1 (top panel) or 
Cisplatin-Etoposide (lower panel) and IC50s were determined by cell viability assay. Each 
data point is shown as mean +/− SEM. Mean IC50s to Cisplatin-Etoposide treatment are 
reported next to cell line name (lower panel)
C) Tumor volume index of hSCLC xenografts grown on nude mice (NCI-H69: left panel; 
GLC16: right panel) as normalized to pre-treatment volume (day 0). Mice were treated with 
vehicle or THZ1. THZ1 was dosed at 10 mg/kg BID and vehicle BID. Inserts show weights 
from mice on treatment
D) Apoptosis assay measuring caspase 3/7 activity in the SCLC cell line NCI-H69 after 
THZ1 treatment for indicated time points.
E) Proliferation assay measuring BRDU incorporation in SCLC cell line NCI-H69 after 
THZ1 treatment for indicated time points.
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F) Western blot detecting RNAPII, CTD phosphorylation (SER-2, SER-5, SER-7), and 
CDK7 along with the apoptotic markers Caspase 3 and PARP in total protein lysates from 
NCI-H69 cell lines exposed to indicated doses of THZ1. ACTIN serves as a loading control.
See also Figure S3.
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Figure 4. THZ1 treatment preferentially targets transcription-regulating genes in SCLC cells
A) Heatmap displaying the Log2 fold-change in gene expression versus DMSO for all active 
transcripts in NCI-H69, GLC16 and NCI-H82 cells following treatment with 25 nM and 100 
nM THZ1 for 6 hours.
B) Box plots of Log2 fold-change in gene expression versus DMSO for all active transcripts 
in NCI-H69, GLC16 and NCI-H82 cells following treatment with 25 nM or 100 nM THZ1 
for 6 hours. Whiskers extend to 1.5x the interquartile range.
C) Enrichment p-values for selected Gene ontology (GO) functional categories of top-5% 
downregulated genes (vs DMSO) of all active transcripts in NCI-H69, GLC16 and NCI-H82 
cells following treatment with 100 nM THZ1 using DAVID software.
See also Table S1, Table S2, Figure S4.
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Figure 5. Super-enhancers in hSCLC cell lines are associated with proto-oncogenic and lineage-
specific transcription factor genes
A) Distribution of H3K27Ac signal at enhancers. Enhancer regions are plotted in increasing 
order based on their input-normalized H3K27Ac signal (length*density) in NCI-H69, 
GLC16 and NCI-H82 cell lines.
B) Enrichment p-values for selected Gene Ontology (GO) functional categories of super-
enhancer-associated genes in NCI-H69, GLC16 and NCI-H82 cell lines using DAVID.
C) Venn diagram showing overlap between identified super-enhancer genes between NCI-
H69, GLC16, and NCI-H82 cell lines.
D) Gene tracks of H3K27Ac ChIP-seq occupancy and super-enhancer associated (top 2 
rows) and typical-enhancer associated (bottom row) gene loci. The x-axis shows genomic 
position and the y-axis shows the signal of binding in 50bp bins in units of reads per million 
bin (rpm/bin). For genes with known focal amplification (MYCN (NCI-H69), MYC (NCI-
H82, GLC16), input DNA signal-subtracted H3K27Ac signal is displayed (See 
Supplemental Experimental Procedures). Gene models are depicted below each track set.
See also Table S3, Figure S5.
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Figure 6. Identification of Super-enhancer-associated genes highly sensitive to THZ1 in SCLC 
cells
A) Gene set enrichment analysis (GSEA) plot showing significant enrichment of super-
enhancer associated gene signature in 100 nM nM THZ1-treated cells relative to DMSO-
treated cells.
B) Box plots of log2 fold-changes in mean transcript abundance of genes associated with the 
total pool of all enhancers (ALL), typical enhancers (TE), top ranked (largest) typical 
enhancers (TOPTE) and super-enhancers (SE) upon treatment with 25 or 100 nM THZ1 
compared to control (DMSO). Whiskers extend to 1.5x the interquartile range.
C) Leading-edge genes identified from enrichment analysis in A) and corresponding 
heatmap of expression ‘leading-edge genes’ in DMSO- and 25 nM and 100 nM THZ1-
treated cells.
D) Venn diagram showing overlap of ‘leading-edge gene’ sets as identified in (A) with the 
top-5% highest-expressed genes for each cell line. Gene names in black bold italics are 
transcription factors, and gene names in black italics are not transcription factors. Gene 
names in gray bold italics are transcription factors associated with a TOPTE.
E) Quantitative PCR to detect expression of indicated gene transcripts in DMSO, 25 nM and 
100 nM THZ1-treated SCLC cells. Target gene expression is normalized to GUSB 
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expression and ‘DMSO’ serve as reference sample set to ‘Relative expression’ index 1). 
Data are presented as mean +/− SEM.
F) Western blotting to detect protein expression of indicated protein in DMSO, 25 nM and 
100 nM THZ1-treated SCLC cells. ACTIN serves as a loading control.
See also Table S4, Figure S6.
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